Gyre Therapeutics GC granted 50,000 stock options

GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share.

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share. These options expire on June 8, 2036. According to the vesting terms, 25% of the grant will vest on June 8, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. After this grant, Bergmann holds 50,000 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Bergmann Joshua Benjamin

Role GC and Corporate Secretary

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Option grant size: 50,000 options Exercise price: $6.05 per share Expiration date: June 8, 2036 +3 more

6 metrics

Option grant size 50,000 options Stock Option (Right to Buy) granted on June 8, 2026

Exercise price $6.05 per share Exercise price of granted stock options

Expiration date June 8, 2036 Option expiration for 50,000-share grant

Initial vesting 25% vests June 8, 2027 First tranche of option vesting

Remaining vesting period 3 years monthly Remaining options vest in equal monthly installments

Holdings after grant 50,000 derivative securities Total options held directly following transaction

Key Terms

Stock Option (Right to Buy), vesting, exercise price, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting financial

"25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 6.0500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Gyre Therapeutics (GYRE) report for Joshua Benjamin Bergmann?

Gyre Therapeutics reported that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options for 50,000 shares. The options are equity compensation, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.

How many Gyre Therapeutics (GYRE) options were granted to Joshua Benjamin Bergmann?

The Form 4 shows Bergmann was granted stock options covering 50,000 shares of Gyre Therapeutics common stock. This entire amount is a single option award and represents his total derivative position immediately after the reported transaction in the filing.

What is the exercise price and expiration date of the GYRE options granted to Bergmann?

The granted stock options have an exercise price of $6.05 per share and expire on June 8, 2036. This means Bergmann can choose to buy Gyre Therapeutics common shares at $6.05 any time before that expiration date, once vested.

How do the Gyre Therapeutics (GYRE) options granted to Bergmann vest over time?

The option grant vests 25% on June 8, 2027, with the remaining 75% vesting in equal monthly installments over the next three years. Vesting is contingent on Bergmann’s continued service to Gyre Therapeutics through each applicable vesting date.

Did Joshua Benjamin Bergmann buy or sell GYRE shares in the market in this Form 4?

No open-market buy or sell is reported; the Form 4 shows a compensation-related grant of stock options. Code “A” denotes a grant or award, so this filing reflects an option award rather than a purchase or sale of existing common shares.

What role does Joshua Benjamin Bergmann hold at Gyre Therapeutics (GYRE) in this Form 4?

The filing identifies Joshua Benjamin Bergmann as an officer of Gyre Therapeutics, serving as GC and Corporate Secretary. The reported stock option grant is part of his equity compensation in that officer capacity, subject to the vesting schedule described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bergmann Joshua Benjamin

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GC and Corporate Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.05	06/08/2026		A		50,000		(1)	06/08/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Thomas Eastling, as attorney-in-fact for Joshua Bergmann	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)